What the published research actually administered — and to what.

The short version

No validated human dose exists for the BPC-157 + TB-500 blend. The numbers that circulate in research communities are extrapolated from rodent studies and, for the thymosin beta-4 side, from ophthalmic trials that delivered a topical eye-drop solution — not a systemic injection.

For BPC-157, the value that recurs across the Zagreb laboratory's animal program is 10 micrograms per kilogram of body weight, given intraperitoneally to rats, once daily. BPC-157 breaks down quickly — its half-life in animals is under 30 minutes. For full-length thymosin beta-4, human intravenous Phase 1 studies gave single doses from 42 to 1,260 milligrams; the ophthalmic trials used a 0.1 percent topical solution. None of those numbers is the TB-500 fragment, and none is the blend.

This page reports what was studied, in which species, and at which doses. It does not translate those figures into a use schedule, because the literature does not support that translation.

How to read this page

The doses below are research-context values pulled from the cited papers. They were administered to laboratory animals (predominantly Wistar rats) or, in the case of the thymosin beta-4 ophthalmic trials, to human eyes as a topical solution. None of these values constitute a human systemic protocol, and no FDA-approved human dose exists for either BPC-157 or TB-500. The protocols that circulate online for the BPC-157 + TB-500 blend are not based on controlled human pharmacokinetic data and are not the subject of this page.

The site reports what was studied. It does not translate those studies into a use schedule.

BPC-157 — the dose that appears most often

Across the Sikiric-lab program for tendon, ligament, muscle, and gastrointestinal models, the value that recurs is 10 μg/kg intraperitoneal, once daily. The Achilles tendon-to-bone paper tested 10 μg/kg, 10 ng/kg, and 10 pg/kg in Wistar rats, with the μg/kg dose producing the cleanest functional, biomechanical, and histological improvement and partially offsetting corticosteroid-induced healing impairment ^[1]. The medial collateral ligament paper used the same 10 μg/kg and 10 ng/kg intraperitoneal doses ^[2]. The muscle-crush paper used 10 μg/kg intraperitoneal once daily for 14 days, with parallel topical-cream arms ^[3].

Non-injectable routes have also been studied in rodents. The ligament paper reported equivalent functional outcomes when BPC-157 was applied topically at 1.0 μg dissolved per gram of neutral cream, and when administered orally at approximately 0.16 μg/mL in drinking water ^[2]. The colitis paper used a 10 μg/kg topical bath (1 mL per rat) to restore colonic blood supply ^[6]. The in-vitro fibroblast paper used 0.1–0.5 μg/mL in cell culture to up-regulate growth hormone receptor expression ^[5]. The vascular ex-vivo work used 10–100 μg/mL in aortic-ring and HUVEC preparations ^[4]. These are bench values, not in-vivo systemic doses.

BPC-157's plasma half-life in preclinical work is reported as under 30 minutes, with hepatic metabolism and renal clearance ^[16]. The compound is reported to be stable in human gastric juice, which underlies the oral preclinical protocols ^[6][16].

TB-500 and full-length thymosin beta-4

The TB-500 fragment and the full-length Tβ4 parent peptide are dosed differently in the published literature, and the difference matters for any honest reading of online protocols.

In the rat embolic-stroke model, full-length Tβ4 was administered at 6 mg/kg intraperitoneally, first dose 24 hours after middle-cerebral-artery occlusion and then every three days for four doses ^[11]. In adult-epicardial-progenitor work, Tβ4 was administered at 150 μg per mouse intraperitoneally in a repeated-dose protocol ^[10]. In the Bock-Marquette cardiac paper, both intracardiac and intraperitoneal delivery were used in the experimental model ^[9]. These are systemic doses of the full-length peptide, not the LKKTETQ fragment.

In human ophthalmic trials, the formulation was a 0.1% topical Tβ4 ophthalmic solution (RGN-259) dosed five times daily for four weeks in neurotrophic keratopathy ^[14] and six times daily for 28 days in dry-eye disease ^[15]. Both are topical eye-drop applications; neither is a systemic dose. The dermal Phase 2 work used topical formulations in pressure ulcers, stasis ulcers, and epidermolysis bullosa ^[12]. None of the published human protocols is an injectable systemic regimen.

Thymosin beta-4 is short-lived in circulation; the short half-life of both BPC-157 and Tβ4/TB-500 is cited across the online literature as a key limitation for any translational dosing claim.

What the literature does not contain

There is no FDA-approved human systemic dose for BPC-157 or TB-500. There is no controlled human pharmacokinetic study that establishes an evidence-based dosing schedule for the BPC-157 + TB-500 blend. There is no controlled in-vivo study comparing the blend against either peptide as monotherapy ^[18]. The vendor research-vial ratios most commonly reported online (5 mg : 5 mg or 5 mg : 10 mg per vial) are not based on a published combination protocol; they are commercial conventions.

The 2025 scoping review by McGuire and colleagues confirms what a careful reading of the corpus already suggests: the human evidence for BPC-157 is limited to three small pilot studies (knee pain, interstitial cystitis, intravenous safety), the plasma half-life is under 30 minutes, and the compound should be considered investigational pending large-scale human trials ^[16]. The 2025 systematic review of orthopaedic-sports-medicine use makes the same point in a more pointed register: off-label clinical use is outpacing the human evidence base ^[19].

Readers of online protocols should treat any translation of the rodent doses to a human μg/kg or mg/dose schedule as an extrapolation made without supporting pharmacokinetic data. This publication does not perform that extrapolation.